S100β as a serum marker in endocrine resistant breast cancer

S100β as a serum marker in endocrine resistant breast cancer

Abstract Background Endocrine therapy is standard treatment for estrogen receptor (ER)-positive breast cancer. However, its efficacy is limited by intrinsic and acquired resistance. Here the potential of S100β as a biomarker and inhibition of its signaling network as a therapeutic strategy in endocr...

Full description

Bibliographic Details
Main Authors: Sara Charmsaz, Éamon Hughes, Fiona T. Bane, Paul Tibbitts, Marie McIlroy, Christopher Byrne, Sinéad Cocchiglia, Jean McBryan, Bryan T. Hennessy, Róisín M. Dwyer, Michael J. Kerin, Arnold D. Hill, Leonie S. Young
Format: Article
Language:English
Published: BMC 2017-04-01
Series:BMC Medicine
Subjects:
Biomarker
Endocrine resistance
Breast cancer
S100β
Estrogen receptor
Online Access:http://link.springer.com/article/10.1186/s12916-017-0836-2

Internet

http://link.springer.com/article/10.1186/s12916-017-0836-2

Similar Items